The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.

Our analysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.

Management completed the divestiture of non-core hardware assets to Companion Spine for $21.4 million, allowing for a sharpened focus on the core high-margin biologics business.

The company secured exclusive U.S. distribution rights for HEMOBLAST Bellows, marking a strategic entry into the multibillion-dollar hemostatic agent market.

Performance in Q1 was impacted by the cessation of Q-code license revenue and headwinds in the advanced wound care market affecting amnio product revenue.

Xtant is aggressively expanding its commercial reach by doubling regional sales reps and integrating 21 seasoned professionals from Dilon Technologies.

The launch of Trivium Shaped expands the biologics portfolio by offering pre-shaped configurations that improve surgical workflow and consistency in the operating room.

Management positions the company as a 'partner of choice' for hospital systems by offering a comprehensive suite across all five major orthopedic biologic categories.

Strategic debt reduction of $13.3 million in Q1 was prioritized to lower interest expenses and improve the overall flexibility of the balance sheet.

Full-year 2026 revenue guidance was raised to a range of $101 million to $105 million, reflecting the addition of HEMOBLAST and base business growth.

Management expects biologics growth to accelerate throughout the remainder of 2026, driven by new product introductions and sales force investments.

Gross margins are projected to return to the low 60s in the second half of 2026 as product mix improves and one-time Q1 inventory expenses subside.

The company anticipates a recovery in the amnio and advanced wound care business during the second half of the year, following a soft first quarter.

Future commercial strategy involves cross-selling the full biologics bag through the newly acquired Dilon sales team once initial HEMOBLAST targets are met.

The termination of amniotic membrane license agreements at the end of 2025 due to reimbursement changes created a year-over-year margin headwind.

Operating expenses decreased significantly following the sale of the international hardware business and Coflex assets.

A $10.7 million final payment from Companion Spine was utilized to significantly reduce the outstanding balance on the company's revolving credit facility.

Q1 gross margin of 57.3% was negatively impacted by excess and obsolete inventory expenses and the loss of high-margin royalty revenue.

One stock. Nvidia-level potential. 30M+ investors trust Moby to find it first. Get the pick. Tap here.

Management plans to introduce HEMOBLAST into the spine market, which is the largest segment for hemostatic agents, while leveraging Dilon's existing footprint in general surgery.

The 21 new sales reps will initially focus on HEMOBLAST and complementary amnio/collagen lines before eventually carrying the full Xtant product portfolio.

The addition of the Dilon sales team and associated marketing costs is expected to increase sales and marketing expenses by approximately $2.5 million per quarter.

Growth is currently driven by advanced biologics like OsteoFactor Pro and the Trivium line, while the stem-cell segment saw Q1 softness due to lumpy OEM orders.

Management expects the advanced wound care market to stabilize in the second half of 2026, aligning with broader industry trends.

Trivium Shaped serves as a high-end, advanced alternative to traditional 510(k) putties and the company's legacy 3Demin product line.

The product is designed to enhance surgical convenience by providing ready-to-use forms like boats and strips, optimizing operating room workflow.